Table 2 Predictive factors correlation ranking for the 3- and 12-month time points by LASSO

From: LASSO NTCP predictors for the incidence of xerostomia in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma

XER HNSCC-3m

   

1. Dmean-c

6. Education

11. Smoking

16. Node classification

2. Dmean-i

7. Marriage

12. Gender

17. Family history

3. Age

8. Chemotherapy

13. Baseline xerostomia

 

4. T stage

9. Financial status

14. Surgery

 

5. Tumor site

10. SIB or SQM

15. Alcohol abuse

 

XER NPC-3m

   

1. Dmean-c

5. Education

9. T stage

13. Alcohol abuse

2. Dmean-i

6. Baseline xerostomia

10. Smoking

14. SIB or SQM

3. Financial status

7. Gender

11. Family history

15. Chemotherapy

4. Age

8. Node classification

12. Marriage

 

XER HNSCC-12m

   

1. Dmean-c

6. Smoking

11. Gender

16. Chemotherapy

2. Dmean-i

7. Education

12. Alcohol abuse

17. Node classification

3. T stage

8. Family history

13. Surgery

 

4. Tumor site

9. Financial status

14. Marriage

 

5. Age

10. Baseline xerostomia

15. SIB or SQM

 

XER NPC-12m

   

1. Dmean-c

5. Financial status

9. T stage

13. Chemotherapy

2. Dmean-i

6. SIB or SQM

10. Marriage

14. Family history

3. Education

7. Baseline xerostomia

11. Alcohol abuse

15. Gender

4. Age

8. Smoking

12. Node classification

 
  1. Abbreviation: Dmean-c: the mean dose given to the contralateral parotid gland; Dmean-i: the mean dose given to the ipsilateral parotid gland; SIB: simultaneous integrated boost; SQM: sequential mode; HNSCC: head and neck squamous cell carcinoma; NPC: nasopharyngeal carcinoma; LASSO: least absolute shrinkage and selection operator; XER: Xerostomia; XER3m or 12m: patient-reported moderate- to-severe xerostomia after 3- or 12-month; Chemotherapy: patients received concurrent chemotherapy.
Back to article page